叮当健康(09886.HK)公布年度业绩：总收入48.57亿元同比增长12.2%，净亏损大幅收窄91.9%，注册用户与医疗问诊服务同步增长
格隆汇3月28日丨叮当健康(09886.HK)公布年度业绩，截至2023年12月31日止年度，集团总收入增至人民币48.568亿元，同比增长12.2%；注册用户与医疗问诊服务同步增长，累计注册用户达到约4150万人，并于在线问诊业务录得821万次健康咨询及问诊。截至2023年12月31日止年度内，公司净亏损水平收窄91.9%，同比减亏人民币26.114亿元，录得亏损人民币2.309亿元，经调整亏损率为2.2%，同比减少0.8百分点，主要得益于公司的降本增效经营策略，有效提升了运营效率。
截至2023年12月31日止年度内，集团的快药业务仍保持增长，按照渠道划分的收入明细包括，线上直营方面录得收入人民币35.279亿元，同比增长14.1%；业务分销录得收入人民币5.458亿元，同比增长25.0%；线下零售收入录得人民币6.439亿元，同比减少4.5%；以及其他业务录得收入人民币1.392亿元，同比增长9.2%。
报吿期内，集团加强自身供应链体系建设，包括仓储物流以及冷链物流服务能力，在包括糖尿病、皮肤病等专科领域，以数字化+专业物流方式，进一步提升用户服务能力，保障用户的安全用药。通过与超过6,000家制药及分销企业合作，集团着力于拓展合作伙伴关系，共同提升及扩大产品组合的多样性，并建立了「药交汇」创新业务平台，提供多渠道、高品质的健康商品。
报吿期内，集团启动了叮当HealthGPT，并首推基于此研发的应用型医药AI产品 －「叮当药师」、「营养师AI助手」。未来，集团将更好地为万千百姓提供专业、便捷、安全的用药、营养保健等服务，进一步实现AI在医药领域的「技术普惠」。「叮当药师」、「营养师AI助手」目前已通过国家执业药师、营养师职业资格考试的模拟考试，并不断升级调优。「叮当药师」、「营养师AI助手」可以高效地调度和分析数据资源，构建交互思考能力，来帮助药师、营养师提高工作效率和服务质量。集团的医疗团队包括超过800名的内外部医生，以及超过400名的医疗专业药师覆盖集团的智慧药房网络，使集团能够按照国家的监管要求，为用户提供安全、有保障的健康服务。报吿期内，集团共提供了超过821万次在线问诊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
